| Literature DB >> 16823925 |
Oliver Pérez1, Gustavo Bracho, Miriam Lastre, Caridad Zayas, Domingo González, Danay Gil, Judith del Campo, Reinaldo Acevedo, Carlos Taboada, Tamara Rodríguez, María E Fajardo, Gustavo Sierra, Concepción Campa, Nestor Mora, Ramón Barberá, Rosa L Solís.
Abstract
Proteoliposome (PL) has been recently used as a protective intramuscular (i.m.) anti-meningococcal BC vaccine. It induces a preferential Th 1 type of immune response. Nevertheless, mucosal protection is mainly mediated by IgA antibody response, which is not usually induced by i.m. vaccination route. IgA antibody production needs the stimulation of Th3 subpopulation, which is also related to the induction of small dose tolerance. We hypothesized that PL-derived Cochleate can induce a specific mucosal IgA and systemic IgG antibody responses. We could show that mice immunized with two or three intranasal doses of PL-derived Cochleate developed significantly increased levels of local anti PL IgA and systemic IgG antibody responses. Thus, our results suggest that PL-derived Cochleate can be used as a promising immunomodulator and delivery system for the development of mucosal, particularly nasal vaccines.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16823925 DOI： 10.1016/j.vaccine.2005.01.127
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641